Brief: Shanghai Henlius Biotech SAys FDA Approves IND Application For Henlius' Biosimilar Hlx17
08/09/2025 11:45
Sept 8 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK: FDA APPROVES IND APPLICATION FOR HENLIUS' BIOSIMILAR HLX17 IND APPLICATION FOR PHASE 1 TRIAL OF BIOSIMILAR OF PEMBROLIZUMAB HLX17 APPROVED BY FDA Further company coverage: 2696.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln